XOPENEX HFA(TM) Metered-Dose Inhaler Now Available by Prescription for Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD) Symptoms
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec. 12, 2005--Sepracor Inc. (Nasdaq: SEPR) today announced that XOPENEX HFA(TM) (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI), is now available by prescription in pharmacies nationwide. XOPENEX HFA is a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. The XOPENEX HFA MDI is a portable, hand-held device consisting of a pressurized canister containing medication and a mouthpiece through which the medicine is inhaled.
Working mother of 3 asthmatic boys - two of whom are also on the autism spectrum - tries to make it all work, keep her monkeys healthy, and figure out the cause of (and solution to) the asthma and autism epidemics. Because being the working mother of 3 just wasn't ENOUGH work.
Friday, December 30, 2005
Xopenex MDI
Check it out - now you can have kids who can breathe in under fifteen minutes -- without turning them into hyperactive nightmares.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment